Eli Lilly's Incoming CEO May Carry First Alzheimer's Drug Across The Finish Line
With more than four months left until David Ricks becomes Eli Lilly's top executive, his eventual legacy is already being shaped by the struggle to find an elusive treatment for a horrific disease.
Ricks, the leader of Eli Lilly and Co.'s largest business unit, is set to become Lilly's 11th CEO on Jan. 1. That's just days after the Indianapolis pharmaceutical giant is expected to release initial results on a highly anticipated Alzheimer’s disease drug called solanezumab.
Ricks, the leader of Eli Lilly and Co.'s largest business unit, is set to become Lilly's 11th CEO on Jan. 1. That's just days after the Indianapolis pharmaceutical giant is expected to release initial results on a highly anticipated Alzheimer’s disease drug called solanezumab.